Late stent thrombosis is one of the most serious complications associated with morbidity and mortality after coronary drug-eluting stent implantation, and is mainly caused by the withdrawal of antiplatelet agents. We report our experience of late stent thrombosis simultaneously involving three different coronary arteries in a young male patient who was treated with three drug-eluting stents two years ago. The patient stopped taking antiplatelet agents for several days. The patient did not recover from cardiogenic shock, even after repeated ballooning with thrombus aspiration, intra-aortic balloon pumping, and temporary pacing during cardiopulmonary resuscitation. 
Introduction
Since the initial introduction of drug-eluting stents (DES), their use has increased rapidly because the clinical and angiographic outcomes have been favorable. [1] [2] [3] However, random trials with strict inclusion criteria have revealed that the incidence of thrombosis associated with DES is not different from bare-metal stents (BMS). 4)5) In the clinical setting, this finding may be relevant because complex lesions, the length or extent of the occluded lesion, the underlying disease, and the compliance of patients has more influence on stent thrombosis than the material from which stents are made. [6] [7] [8] Late stent thrombosis is an especially remarkable severe complication of DES, which has caused myocardial infarctions or deaths, and these events have been mainly associated with the withdrawal of antiplatelet agents.
9)10)
We will report our experience with late stent thrombosis simultaneously involving three different coronary arteries after cessation of an antiplatelet agent for several days in a young patient treated with DES implantation.
Case
A 35 year-old man with a history of heavy smoking presented to the emergency room with the sudden onset of chest pain of 2 hours duration. The electrocardiogram (ECG) obtained in the emergency room showed STsegment elevation in the anterior and inferior leads. Two years previously, he was admitted with similar symptoms at another hospital. The ECG at that time showed T wave inversion in the inferior leads (Fig. 1) . Coronary angiography (CAG) revealed the presence of three vessel disease with total occlusion of the middle right coronary artery (RCA) and critical stenosis in the proximal left ascending coronary artery (LAD) and intermediate branch. Immediately after the CAG, percutaneous coronary intervention (PCI) for mid -RCA was performed with a 3.0×28 mm Taxus stent (Boston Scientific, Boston, MA, USA). One week later, the follow-up angiography for the RCA lesion revealed a patent stent and a second stage PCI for the proximal LAD and intermediate branch lesions was performed with 3.5×24 mm and 3.0×24 mm Taxus stents, respectively. The final CAG showed no residual stenosis with good distal flow (Fig. 2) .
Twenty months after the initial procedure, the patient was transferred to our hospital with an acute inferior wall ST elevation myocardial infarction (STEMI) after emergency treatment with a thrombolytic agent {Tenec- He complained of chest pain continuously during the 3 hours prior to thrombolytic therapy. The follow-up ECG obtained in our hospital showed persistent ST elevation in the inferior leads (Fig. 3) , the cardiac enzymes as (CK, CK-MB, and troponin-I) were elevated, and echocardiography also showed hypokinetic movement of the inferoposterior wall. After loading with 300 mg of aspirin and 300 mg of clopidogrel, he was taken directly to the catheterization room for rescue PCI. The CAG showed patency in the previously stented sites of the middle RCA, proximal LAD, and intermediate branch, with good distal flow (Fig. 4) . Gradually, the chest pain and ST elevation on the ECG resolved. The post-treatment clinical course was uneventful and the patient was discharged 2 weeks later on dual antiplatelet agents {aspirin (100 mg) and clopidogrel (75 mg)}.
Four months after the second diagnostic CAG, the patient presented to the emergency room with an inferior and anteroseptal wall STEMI. He complained of severe chest pain and dyspnea, and dull mental status, and became stuporous in the emergency room. He had not taken his medication over several days because of a disregard for his health, including the heavy consumption of alcohol. The ECG showed complete AV block, a right bundle branch block, and ST-segment elevation in both the anterior and inferior leads (Fig. 5) . The systolic blood pressure decreased to 60 mmHg and the heart rate dropped to 25 beats/min. Several minutes later, the patient's mental state changed to coma and his blood pressure was not checked. Cardiopulmonary resuscitation (CPR) was started promptly and he was transferred to the catheterization room. His condition deteriorated further, so CPR was continued. An emergency CAG revealed simultaneous total occlusion of the middle RCA, proximal LAD, and intermediate branch, the previously paced sites of the deployed sites of the Taxus stents. After insertion of an intra-aortic balloon coun- was not recovered, despite continuous thrombus aspiration and repeated ballooning (Fig. 6) . Unfortunately, the patient died in the catheterization room.
Discussion
Stent thrombosis is one of the most severe complications associated with morbidity and mortality after DES or BMS implantation.
11) By definition, early stent thrombosis occurs within 30 days after stent implantation, while late stent thrombosis occurs beyond 30 days. 12) Additionally, very late stent thrombosis is defined as a thrombus occurring beyond 1 year. Early stent thrombosis occurs in about 1.0-1.5% of patients with DES; the probability of occurrence with a BMS is similar. In the largest series of eight cases, late stent thrombosis unexpectedly occurred in 0.35-0.72% of patients with DES. In addition, most cases have been associated with discontinuation of antiplatelet therapy late after stent implantation.
13)14)
Delayed re-endothelialization of the stent, because of the antiproliferative nature of the agents, appears to be implicated in the pathophysiology of very late stent thrombosis. On the basis of this theory, DES causes delayed arterial healing and increased inflammatory reactions compared to BMS, so DES seems to be associated with higher rates of late stent thrombosis than BMS. 15) Unlike DES, the overall rate of stent thrombosis which occurs in patients with BMS is the subject of but few reports. However, some recent studies have reported that there are no differences in the incidences of late stent thrombosis between patients treated with DES and BMS. 11) In the clinical setting, acute coronary syndrome, bifurcation treatment, diabetes, and premature discontinuation of antiplatelet therapy are considered strong predictors of stent thrombosis. Effective antiplatelet agents have a critical role in the prevention of stent thrombosis. [6] [7] [8] Therefore, in most cardiac centers prolonged dual antiplatelet therapy with aspirin and clopidogrel is recommended for the prevention of stent thrombosis after PCI.
Previously, some studies have reported that aspirin withdrawal after PCI increases the occurrence of a coronary event, such as stent thrombosis. 6)9)13) A study noted that aspirin withdrawal in patients with coronary artery disease increased morbidity within 1 month after cessation of aspirin, whether treated by BMS or DES, 16) and another study reported that eight cases occurred during late stent thrombosis after the withdrawal of aspirin.
14) Yet another study noted that the inadvertent interruption of clopidogrel therapy also can induce late stent thrombosis. 17) Dual antiplatelet therapy can prevent stent thrombosis, but withdrawal of any one agent could result in the cardiovascular events at any time.
Even if a patient had a coronary stent deployed before elective non-cardiac surgery, aspirin should not be discontinued, except for intracranial neurosurgery and transureteral prostectomy. A recent review proved that aspirin neither increased the perioperative severity nor the mortality associated with bleeding. 18) In addition, whatever non-cardiac surgery is planned, it must be performed later than 6 weeks after stent implantation if possible, because stent thrombosis frequently develops within 3-6 weeks of a cardiac procedure. 19) These events have been mainly related to insufficient stent re-endothelialization, heightened platelet reactivity, and withdrawal of the antiplatelet agent.
In this case, our patient did not take his prescribed medication continuously in spite of prescription of dual antiplatelet agents after the second attack, and he died due to very late stent thrombosis of three different coronary arteries at the same time, two years after DES implantation.
In summary, this case emphasizes that late stent thrombosis should be considered in all patients treated with coronary DES implantation, and may be prevented by using an antiplatelet agent continuously.
